Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Andersen, Christen Lykkegaard ^a,b   Lindegaard, Hanne ^c   Vestergaard, Hanne ^c   Siersma, Volkert Dirk ^b   Hasselbalch, Hans Carl ^a   De Fine Olivarius, Niels ^b   Bjerrum, Ole Weis ^d   Junker, Peter ^c  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGE; ARTICLE; CANCER REGISTRY; CANCER RISK; COMORBIDITY; DISEASE DURATION; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; GENDER; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; ONSET AGE; PRIMARY MEDICAL CARE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SOLID TUMOR; ARTHRITIS, RHEUMATOID; CELL COUNT; COMPLICATION; DENMARK; INCIDENCE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ARTHRITIS, RHEUMATOID; CELL COUNT; DENMARK; FEMALE; HUMANS; INCIDENCE; LYMPHOMA; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84902590485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099388     Document Type: Article

References (38)

1. Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, et al. (2013) Subsequent leukaemia in autoimmune disease patients. Br J Haematol 161: 677-687.
2. Chakravarty EF, Michaud K, Wolfe F (2005) Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32: 2130-2135. (Pubitemid 41587856)
3. Khurana R, Wolf R, Berney S, Caldito G, Hayat S, et al. (2008) Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 35: 1704-1708.
4. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, et al. (2013) Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 52: 91-98.
5. Askling J (2007) Malignancy and rheumatoid arthritis. Curr Rheumatol Rep 9: 421-426.
6. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, et al. (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54: 692-701.
7. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R (2014) Lymphoma development in patients with autoimmune and inflammatory disorders - what are the driving forces? Sem Cancer Biol 24: 61-70.
8. Ekstrom K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, et al. (2003) Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 48: 963-970. (Pubitemid 36418238)
9. Chen YJ, Chang YT, Wang CB, Wu CY (2011) The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum 63: 352-358.
10. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285. (Pubitemid 43736578)
11. Cush JJ, Dao KH (2012) Malignancy risks with biologic therapies. Rheum Dis Clin North Am 38: 761-770.
12. Franklin J, Lunt M, Bunn D, Symmons D, Silman A (2006) Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 65: 617-622.
13. Smedby KE, Baecklund E, Askling J (2006) Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prevention 15: 2069-2077. (Pubitemid 44877028)
14. Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56: 1433-1439. (Pubitemid 46764070)
15. Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, et al. (2013) Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death. American journal of hematology 88: 843-847
16. Gotlib J (2014) World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 89: 325-337.
17. Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133: 468-492.
18. Cools J (2005) The hypereosinophilic syndrome: idiopathic or not, that is the question. Haematologica 90: 582-584.
19. Jacobsen EA, Helmers RA, Lee JJ, Lee NA (2012) The expanding role(s) of eosinophils in health and disease. Blood 120: 3882-3890.
20. Kargili A, Bavbek N, Kaya A, Kosar A, Karaaslan Y (2004) Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Rheumatol Int 24: 321-324. (Pubitemid 40378884)
21. Panush RS, Franco AE, Schur PH (1971) Rheumatoid arthritis associated with eosinophilia. Ann Intern Med 75: 199-205.
22. Haut ER, Pronovost PJ (2011) Surveillance bias in outcomes reporting. JAMA: 305: 2462-2463.
23. Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39: 42-45.
24. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39: 30-33.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40: 373-383. (Pubitemid 17055592)
26. Pedersen M, Klarlund M, Jacobsen S, Svendsen AJ, Frisch M (2004) Validity of rheumatoid arthritis diagnoses in the Danish National Patient Registry. Eur J Epidemiol 19: 1097-1103.
27. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B 57: 289-300.
28. Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, et al. (2008) Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 37: 388-397. (Pubitemid 351734521)
29. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, et al. (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64: 699-703. (Pubitemid 40559295)
30. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, et al. (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A: 1753-1757. (Pubitemid 26306889)
31. Woodward M (2005) Epidemiology: Study Design And Data Analysis. Chapman & Hall/CRC: 278-280.
32. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, et al. (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308: 898-908.
33. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, et al. (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73: 529-535.
34. Lichtman MA (2010) Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 15: 1083-1101.
35. Morton LM, Hartge P, Holford TR, Holly EA, Chiu BC, et al. (2005) Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). Cancer Epidemiol Biomarkers Prev 14: 925-933. (Pubitemid 40478558)
36. The Danish Cancer Registry 2010. http://www.sst.dk/publ/Publ2011/DAF/ Cancer/Cancerregisteret2010.pdf
37. Simonsson M, Bergman S, Jacobsson LT, Petersson IF, Svensson B (1999) The prevalence of rheumatoid arthritis in Sweden. Scand J Rheumatol 28: 340-343. (Pubitemid 30033046)
38. The nationwide Danish DANBIO registry. https://danbio-online.dk/Danbio- yearly-report-2007-eng.pdf/view